Antibiotic consumption and antimicrobial resistance in the SARS-CoV-2 pandemic: A single-center experience
Open Access
- 15 March 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1067973
- https://doi.org/10.3389/fphar.2023.1067973
Abstract
Antimicrobial resistance and the rapid spread of multiresistant bacteria represent one of the main public health problem in limited resources countries. This issue is significantly worsening since the COVID-19 pandemic due to the unreasonably increased antibiotics prescription to patients with confirmed SARS-CoV-2 infection. The aim of this study was to examine whether COVID-19 pandemic (2020, 2021) was associated with increased antibiotic consumption in inpatient and outpatient settings in the middle size urban region (Republic of Srpska/Bosnia and Herzegovina) in comparison to period before the pandemic (2019). Additionally, we aimed to determine antimicrobial resistance and the presence of multiresistant bacteria in the regional hospital ("Saint Apostol Luka" Hospital Doboj) in 2021. Antibiotic consumption in hospital setting registered during 2019, 2020 and 2021 was as follows: carbapenems (meropenem: 0.28; 1.91; 2.33 DDD/100 bed-days, respectively), glycopeptides (vancomycin: 0.14; 1.09, 1.53 DDD/100 bed-days, respectively), cephalosporins (ceftriaxone: 6.69; 14.7; 13.9 DDD/100 bed-days, respectively) and polymyxins (colistin: 0.04; 0.25; 0.35 DDD/100 bed-days, respectively). Consumption of azithromycin increased drastically in 2020, and dropped significantly in 2021 (0.48; 5.61; 0.93 DDD/100 bed-days). In outpatient setting, an increase in the consumption of oral forms of azithromycin, levofloxacin and cefixime, as well as parenteral forms of amoxicillin-clavulanic acid, ciprofloxacin and ceftriaxone, was recorded. In 2021, antimicrobial resistance to reserve antibiotics in hospital setting was as follows: Acinetobacter baumanii to meropenem 66.05%, Klebsiella spp to ceftriaxone 67.14%, Pseudomonas to meropenem 25.7%. Recent COVID-19 pandemic was associated with increased antibiotic consumption in inpatient and outpatient settings, with characteristic change of pattern of azithromycin consumption. Also, high levels of antimicrobial resistance to reserve antibiotics were registered in hospital setting with low prevalence of identified pathogen-directed antimicrobial prescription. Strategies toward combat antimicrobial resistance in the Doboj region are urgently needed.This publication has 17 references indexed in Scilit:
- Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 PandemicAntibiotics, 2021
- Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?Journal of Infection and Public Health, 2021
- Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 PandemicAntibiotics, 2021
- Evolution of Antimicrobial Consumption During the First Wave of COVID-19 PandemicAntibiotics, 2021
- Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settingsInternational Journal of Infectious Diseases, 2021
- Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing GuidelinesDrug Safety, 2020
- COVID-19 and the potential long-term impact on antimicrobial resistanceJournal of Antimicrobial Chemotherapy, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkitJAC-Antimicrobial Resistance, 2019
- The World Health Organization Global Action Plan for antimicrobial resistanceSouth African Medical Journal, 2015